Dihydromyricetin powder's functions have already been described by us in the last article, including liver protection and gallbladder, anti-tumor effect, antioxidant effect, and antibacterial effect. As researchers continue to deepen their research on dihydromyricetin, DHM will create greater value in the medical field.
Recent research has found that Dihydromyricetin has shown promising therapeutic effects in addressing both neurological and hepatic disorders. Studies highlight its ability to modulate hippocampal GABAergic neurotransmission and gephyrin levels, effectively reducing anxiety symptoms. Simultaneously, dihydromyricetin demonstrates anti-inflammatory and antifibrotic properties by inhibiting NF-κB-mediated inflammation and regulating TGF-β1 and PI3K/Akt signaling pathways, reversing thioacetamide-induced liver fibrosis. These findings suggest that dihydromyricetin holds potential as a dual-action remedy for improving mental health and liver function.
Dihydromyricetin Reduces Anxiety by Regulating Brain Neurotransmitters
Anxiety disorders are a group of mental disorders that are the leading cause of disability in Western society. Anxiety disorders, including generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder and phobias, usually early onset, chronic or recurrent, causing severe personal distress and impairing social and social skills. professional function, reduce the quality of life and cause a huge financial burden. These disorders cost the United States more than $42 billion a year, representing nearly one-third of the country's total mental health expenditure.
The present study demonstrates through a series of experiments that DHM treatment restores ATP and gephyrin expression, GABAergic transmission and synaptic function, and reduces anxious behaviors. The results suggest a broader role of DHM in anxiolysis, GABAergic neurotransmission and synaptic function. DHM is a potential candidate for the pharmacotherapy of anxiety disorders.
Dihydromyricetin Reverses Liver Fibrosis by Reducing Inflammation
As an important immune and metabolic organ of the human body, the liver is vulnerable to damage from various causes, including hepatitis virus infection, alcohol and drug injury, autoimmune response, and metabolic diseases. As a potent hepatotoxin, TAA-induced liver fibrosis is a well-recognized model for the development of liver damage, regenerative nodules, and fibrosis, similar to human liver fibrosis. Numerous experiments have shown that long-term administration of TAA leads to proliferative liver nodules, liver fibrosis, hepatocellular adenomas, and hepatocellular carcinoma.
This study demonstrated that DHM treatment effectively reduced markers of oxidative stress and improved damaged liver architecture and hepatotoxicity. More importantly, DHM reversed TAA-induced liver fibrosis by inhibiting NF-κB-mediated inflammation and apoptotic proteins downstream of the TGF-β1-regulated PI3K/Akt signaling pathway, which also suggests that DHM may be a potential Anti-chronic liver disease active substance.
TIPS
If you want to learn more about dihydromyricetin powder, Please feel free to contact us at sales@kintaibio.com or feedback on the next page.
For more details, please check www.kintai-bio.com.
